The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo …
PJ Hesketh, SM Grunberg, RJ Gralla… - Journal of clinical …, 2003 - ascopubs.org
Purpose: In early clinical trials with patients receiving highly emetogenic chemotherapy, the
neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic …
neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic …
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients …
DG Warr, JC Street, AD Carides - Supportive Care in Cancer, 2011 - Springer
Goals of work A number of prognostic factors have been identified as risk factors for
chemotherapy-induced emesis. This post-hoc analysis addressed whether:(1) these …
chemotherapy-induced emesis. This post-hoc analysis addressed whether:(1) these …
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) remains a major
adverse effect of cancer therapy. We aimed to determine outcomes associated with use of …
adverse effect of cancer therapy. We aimed to determine outcomes associated with use of …
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy
F Longo, G Mansueto, V Lapadula, R De Sanctis… - Supportive Care in …, 2011 - Springer
Background The combination of a neurokinin-1 receptor antagonist, dexamethasone, and a
5-HT 3 receptor antagonist is currently the standard antiemetic treatment in patients …
5-HT 3 receptor antagonist is currently the standard antiemetic treatment in patients …
Randomized, placebo‐controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed …
JD Herrington, AD Jaskiewicz, J Song - Cancer, 2008 - Wiley Online Library
BACKGROUND. The combination of palonosetron and aprepitant is safe and effective in the
prevention of chemotherapy‐induced emesis (CIE). The purpose of this pilot study was to …
prevention of chemotherapy‐induced emesis (CIE). The purpose of this pilot study was to …
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting
SP Chawla, SM Grunberg, RJ Gralla… - … Journal of the …, 2003 - Wiley Online Library
BACKGROUND The neurokinin‐1 antagonist aprepitant (EMEND™; Merck Research
Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea …
Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea …
The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double …
DG Warr, SM Grunberg, RJ Gralla, PJ Hesketh… - European Journal of …, 2005 - Elsevier
In this work, data from two phase III studies were pooled to further evaluate the NK1
antagonist aprepitant for prevention of cisplatin induced nausea and vomiting. One …
antagonist aprepitant for prevention of cisplatin induced nausea and vomiting. One …
Cost‐effectiveness of aprepitant for the prevention of chemotherapy‐induced nausea and vomiting associated with highly emetogenic chemotherapy
S Moore, J Tumeh, S Wojtanowski, C Flowers - Value in health, 2007 - Wiley Online Library
Objective: Chemotherapy‐induced nausea and vomiting (CINV) is a significant problem for
cancer patients. Aprepitant, a novel NK‐1 receptor antagonist, is approved for use with 5 …
cancer patients. Aprepitant, a novel NK‐1 receptor antagonist, is approved for use with 5 …
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double …
Z Hu, Y Cheng, H Zhang, C Zhou, B Han… - Supportive Care in …, 2014 - Springer
Purpose Aprepitant, an oral neurokinin-1 receptor antagonist, has demonstrated improved
control of chemotherapy-induced nausea and vomiting (CINV) in previous studies. This is …
control of chemotherapy-induced nausea and vomiting (CINV) in previous studies. This is …
Functional relevance of antiemetic control: experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant
AR Martin, AD Carides, JD Pearson, K Horgan… - European journal of …, 2003 - Elsevier
Little information exists on the functional impact of effective antiemetic protection. In the
present study, the Functional Living Index—Emesis (FLIE), was used to assess patient …
present study, the Functional Living Index—Emesis (FLIE), was used to assess patient …